Kairos Pharma, Ltd.
Kairos Pharma, Ltd. KAPA Peers
See (KAPA) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| KAPA | $0.57 | +5.92% | 9.6M | -2.60 | -$0.22 | N/A |
| VRTX | $441.99 | -1.98% | 113.5B | -115.40 | -$3.83 | N/A |
| REGN | $508.97 | -2.62% | 54B | 12.94 | $39.32 | +0.34% |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $308.71 | -0.02% | 40.3B | -147.71 | -$2.09 | N/A |
| ARGX | $540.71 | -1.91% | 33B | 32.95 | $16.41 | N/A |
| BNTX | $104.97 | -1.28% | 25.2B | -28.60 | -$3.67 | N/A |
| BGNE | $184.71 | +0.49% | 20.2B | -22.55 | -$8.19 | N/A |
| RPRX | $34.56 | -1.54% | 19.4B | 14.11 | $2.45 | +2.50% |
| DNA-WT | $0.27 | -2.76% | 18.7B | N/A | N/A | N/A |
Stock Comparison
KAPA vs VRTX Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, VRTX has a market cap of 113.5B. Regarding current trading prices, KAPA is priced at $0.57, while VRTX trades at $441.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas VRTX's P/E ratio is -115.40. In terms of profitability, KAPA's ROE is -0.99%, compared to VRTX's ROE of -0.06%. Regarding short-term risk, KAPA is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs REGN Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, REGN has a market cap of 54B. Regarding current trading prices, KAPA is priced at $0.57, while REGN trades at $508.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas REGN's P/E ratio is 12.94. In terms of profitability, KAPA's ROE is -0.99%, compared to REGN's ROE of +0.15%. Regarding short-term risk, KAPA is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs SGEN Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, KAPA is priced at $0.57, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas SGEN's P/E ratio is -57.19. In terms of profitability, KAPA's ROE is -0.99%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, KAPA is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs ALNY Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, ALNY has a market cap of 40.3B. Regarding current trading prices, KAPA is priced at $0.57, while ALNY trades at $308.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas ALNY's P/E ratio is -147.71. In terms of profitability, KAPA's ROE is -0.99%, compared to ALNY's ROE of -5.09%. Regarding short-term risk, KAPA is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs ARGX Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, ARGX has a market cap of 33B. Regarding current trading prices, KAPA is priced at $0.57, while ARGX trades at $540.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas ARGX's P/E ratio is 32.95. In terms of profitability, KAPA's ROE is -0.99%, compared to ARGX's ROE of +0.23%. Regarding short-term risk, KAPA is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs BNTX Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, BNTX has a market cap of 25.2B. Regarding current trading prices, KAPA is priced at $0.57, while BNTX trades at $104.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas BNTX's P/E ratio is -28.60. In terms of profitability, KAPA's ROE is -0.99%, compared to BNTX's ROE of -0.04%. Regarding short-term risk, KAPA is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs BGNE Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, KAPA is priced at $0.57, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas BGNE's P/E ratio is -22.55. In terms of profitability, KAPA's ROE is -0.99%, compared to BGNE's ROE of -0.12%. Regarding short-term risk, KAPA is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs RPRX Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, RPRX has a market cap of 19.4B. Regarding current trading prices, KAPA is priced at $0.57, while RPRX trades at $34.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas RPRX's P/E ratio is 14.11. In terms of profitability, KAPA's ROE is -0.99%, compared to RPRX's ROE of +0.16%. Regarding short-term risk, KAPA is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs DNA-WT Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, KAPA is priced at $0.57, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, KAPA's ROE is -0.99%, compared to DNA-WT's ROE of -0.63%. Regarding short-term risk, KAPA is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs SMMT Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, SMMT has a market cap of 14.6B. Regarding current trading prices, KAPA is priced at $0.57, while SMMT trades at $19.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas SMMT's P/E ratio is -58.38. In terms of profitability, KAPA's ROE is -0.99%, compared to SMMT's ROE of -0.70%. Regarding short-term risk, KAPA is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs GMAB Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, GMAB has a market cap of 13.7B. Regarding current trading prices, KAPA is priced at $0.57, while GMAB trades at $22.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas GMAB's P/E ratio is 12.96. In terms of profitability, KAPA's ROE is -0.99%, compared to GMAB's ROE of +0.26%. Regarding short-term risk, KAPA is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs INCY Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, INCY has a market cap of 13.3B. Regarding current trading prices, KAPA is priced at $0.57, while INCY trades at $68.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas INCY's P/E ratio is 344.05. In terms of profitability, KAPA's ROE is -0.99%, compared to INCY's ROE of +0.01%. Regarding short-term risk, KAPA is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs UTHR Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, UTHR has a market cap of 12.9B. Regarding current trading prices, KAPA is priced at $0.57, while UTHR trades at $286.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas UTHR's P/E ratio is 11.43. In terms of profitability, KAPA's ROE is -0.99%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, KAPA is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs KRTX Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, KAPA is priced at $0.57, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas KRTX's P/E ratio is -28.09. In terms of profitability, KAPA's ROE is -0.99%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, KAPA is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs EXEL Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, EXEL has a market cap of 11.3B. Regarding current trading prices, KAPA is priced at $0.57, while EXEL trades at $41.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas EXEL's P/E ratio is 18.88. In terms of profitability, KAPA's ROE is -0.99%, compared to EXEL's ROE of +0.29%. Regarding short-term risk, KAPA is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs BMRN Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, BMRN has a market cap of 10.5B. Regarding current trading prices, KAPA is priced at $0.57, while BMRN trades at $55.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas BMRN's P/E ratio is 20.37. In terms of profitability, KAPA's ROE is -0.99%, compared to BMRN's ROE of +0.09%. Regarding short-term risk, KAPA is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs ASND Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, ASND has a market cap of 10.4B. Regarding current trading prices, KAPA is priced at $0.57, while ASND trades at $172.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas ASND's P/E ratio is -25.88. In terms of profitability, KAPA's ROE is -0.99%, compared to ASND's ROE of +1.91%. Regarding short-term risk, KAPA is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs MRNA Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, MRNA has a market cap of 9.9B. Regarding current trading prices, KAPA is priced at $0.57, while MRNA trades at $25.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas MRNA's P/E ratio is -2.93. In terms of profitability, KAPA's ROE is -0.99%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, KAPA is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs RXDX Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, KAPA is priced at $0.57, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas RXDX's P/E ratio is -56.47. In terms of profitability, KAPA's ROE is -0.99%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, KAPA is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs IMGN Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, KAPA is priced at $0.57, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas IMGN's P/E ratio is -111.55. In terms of profitability, KAPA's ROE is -0.99%, compared to IMGN's ROE of -1.43%. Regarding short-term risk, KAPA is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs BPMC Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, BPMC has a market cap of 8.3B. Regarding current trading prices, KAPA is priced at $0.57, while BPMC trades at $128.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas BPMC's P/E ratio is -51.09. In terms of profitability, KAPA's ROE is -0.99%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, KAPA is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs CERE Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, KAPA is priced at $0.57, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas CERE's P/E ratio is -16.47. In terms of profitability, KAPA's ROE is -0.99%, compared to CERE's ROE of -0.43%. Regarding short-term risk, KAPA is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs VRNA Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, VRNA has a market cap of 7.9B. Regarding current trading prices, KAPA is priced at $0.57, while VRNA trades at $92.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas VRNA's P/E ratio is -46.46. In terms of profitability, KAPA's ROE is -0.99%, compared to VRNA's ROE of -0.90%. Regarding short-term risk, KAPA is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs ROIVW Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, ROIVW has a market cap of 7.8B. Regarding current trading prices, KAPA is priced at $0.57, while ROIVW trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, KAPA's ROE is -0.99%, compared to ROIVW's ROE of -0.03%. Regarding short-term risk, KAPA is more volatile compared to ROIVW. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs TECH Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, TECH has a market cap of 7.8B. Regarding current trading prices, KAPA is priced at $0.57, while TECH trades at $49.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas TECH's P/E ratio is 59.64. In terms of profitability, KAPA's ROE is -0.99%, compared to TECH's ROE of +0.06%. Regarding short-term risk, KAPA is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs CORT Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, CORT has a market cap of 7.6B. Regarding current trading prices, KAPA is priced at $0.57, while CORT trades at $71.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas CORT's P/E ratio is 62.48. In terms of profitability, KAPA's ROE is -0.99%, compared to CORT's ROE of +0.20%. Regarding short-term risk, KAPA is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs BBIO Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, BBIO has a market cap of 7.6B. Regarding current trading prices, KAPA is priced at $0.57, while BBIO trades at $40.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas BBIO's P/E ratio is -11.25. In terms of profitability, KAPA's ROE is -0.99%, compared to BBIO's ROE of +0.49%. Regarding short-term risk, KAPA is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs ROIV Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, ROIV has a market cap of 7.6B. Regarding current trading prices, KAPA is priced at $0.57, while ROIV trades at $11.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas ROIV's P/E ratio is -14.81. In terms of profitability, KAPA's ROE is -0.99%, compared to ROIV's ROE of -0.03%. Regarding short-term risk, KAPA is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs RVMD Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, RVMD has a market cap of 7.3B. Regarding current trading prices, KAPA is priced at $0.57, while RVMD trades at $39.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas RVMD's P/E ratio is -9.76. In terms of profitability, KAPA's ROE is -0.99%, compared to RVMD's ROE of -0.37%. Regarding short-term risk, KAPA is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs RETA Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, KAPA is priced at $0.57, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas RETA's P/E ratio is -66.29. In terms of profitability, KAPA's ROE is -0.99%, compared to RETA's ROE of +0.47%. Regarding short-term risk, KAPA is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs HALO Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, HALO has a market cap of 6.5B. Regarding current trading prices, KAPA is priced at $0.57, while HALO trades at $53.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas HALO's P/E ratio is 14.13. In terms of profitability, KAPA's ROE is -0.99%, compared to HALO's ROE of +1.22%. Regarding short-term risk, KAPA is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs JAZZ Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, JAZZ has a market cap of 6.5B. Regarding current trading prices, KAPA is priced at $0.57, while JAZZ trades at $107.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas JAZZ's P/E ratio is 14.54. In terms of profitability, KAPA's ROE is -0.99%, compared to JAZZ's ROE of +0.12%. Regarding short-term risk, KAPA is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs MDGL Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, MDGL has a market cap of 6.2B. Regarding current trading prices, KAPA is priced at $0.57, while MDGL trades at $279.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas MDGL's P/E ratio is -15.66. In terms of profitability, KAPA's ROE is -0.99%, compared to MDGL's ROE of -0.51%. Regarding short-term risk, KAPA is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs IONS Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, IONS has a market cap of 5.8B. Regarding current trading prices, KAPA is priced at $0.57, while IONS trades at $36.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas IONS's P/E ratio is -12.09. In terms of profitability, KAPA's ROE is -0.99%, compared to IONS's ROE of -0.92%. Regarding short-term risk, KAPA is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs TLX Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, TLX has a market cap of 5.6B. Regarding current trading prices, KAPA is priced at $0.57, while TLX trades at $16.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas TLX's P/E ratio is 185.56. In terms of profitability, KAPA's ROE is -0.99%, compared to TLX's ROE of +0.14%. Regarding short-term risk, KAPA is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs TGTX Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, TGTX has a market cap of 5.6B. Regarding current trading prices, KAPA is priced at $0.57, while TGTX trades at $35.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas TGTX's P/E ratio is 140.00. In terms of profitability, KAPA's ROE is -0.99%, compared to TGTX's ROE of +0.19%. Regarding short-term risk, KAPA is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs AMRN Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, AMRN has a market cap of 5.5B. Regarding current trading prices, KAPA is priced at $0.57, while AMRN trades at $13.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas AMRN's P/E ratio is -3.05. In terms of profitability, KAPA's ROE is -0.99%, compared to AMRN's ROE of -0.17%. Regarding short-term risk, KAPA is more volatile compared to AMRN. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs ABCM Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, KAPA is priced at $0.57, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, KAPA's ROE is -0.99%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, KAPA is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs ISEE Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, KAPA is priced at $0.57, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas ISEE's P/E ratio is -22.44. In terms of profitability, KAPA's ROE is -0.99%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, KAPA is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs NUVL Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, NUVL has a market cap of 5.5B. Regarding current trading prices, KAPA is priced at $0.57, while NUVL trades at $76.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas NUVL's P/E ratio is -17.65. In terms of profitability, KAPA's ROE is -0.99%, compared to NUVL's ROE of -0.31%. Regarding short-term risk, KAPA is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs AXSM Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, AXSM has a market cap of 5B. Regarding current trading prices, KAPA is priced at $0.57, while AXSM trades at $101.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas AXSM's P/E ratio is -17.61. In terms of profitability, KAPA's ROE is -0.99%, compared to AXSM's ROE of -3.64%. Regarding short-term risk, KAPA is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs ALKS Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, ALKS has a market cap of 4.9B. Regarding current trading prices, KAPA is priced at $0.57, while ALKS trades at $29.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas ALKS's P/E ratio is 14.18. In terms of profitability, KAPA's ROE is -0.99%, compared to ALKS's ROE of +0.25%. Regarding short-term risk, KAPA is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs ADMA Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, ADMA has a market cap of 4.5B. Regarding current trading prices, KAPA is priced at $0.57, while ADMA trades at $18.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas ADMA's P/E ratio is 22.48. In terms of profitability, KAPA's ROE is -0.99%, compared to ADMA's ROE of +0.72%. Regarding short-term risk, KAPA is more volatile compared to ADMA. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs ALPN Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, KAPA is priced at $0.57, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas ALPN's P/E ratio is -101.52. In terms of profitability, KAPA's ROE is -0.99%, compared to ALPN's ROE of -0.04%. Regarding short-term risk, KAPA is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs AKRO Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, AKRO has a market cap of 4.4B. Regarding current trading prices, KAPA is priced at $0.57, while AKRO trades at $55.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas AKRO's P/E ratio is -14.77. In terms of profitability, KAPA's ROE is -0.99%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, KAPA is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs PCVX Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, PCVX has a market cap of 4.3B. Regarding current trading prices, KAPA is priced at $0.57, while PCVX trades at $33.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas PCVX's P/E ratio is -8.43. In terms of profitability, KAPA's ROE is -0.99%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, KAPA is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs OPT Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, KAPA is priced at $0.57, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas OPT's P/E ratio is -1.52. In terms of profitability, KAPA's ROE is -0.99%, compared to OPT's ROE of +2.60%. Regarding short-term risk, KAPA is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs MRTX Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, KAPA is priced at $0.57, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas MRTX's P/E ratio is -4.82. In terms of profitability, KAPA's ROE is -0.99%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, KAPA is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs ZLAB Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, ZLAB has a market cap of 4.1B. Regarding current trading prices, KAPA is priced at $0.57, while ZLAB trades at $37.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas ZLAB's P/E ratio is -14.89. In terms of profitability, KAPA's ROE is -0.99%, compared to ZLAB's ROE of -0.33%. Regarding short-term risk, KAPA is more volatile compared to ZLAB. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs PTCT Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, PTCT has a market cap of 4B. Regarding current trading prices, KAPA is priced at $0.57, while PTCT trades at $50.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas PTCT's P/E ratio is 7.81. In terms of profitability, KAPA's ROE is -0.99%, compared to PTCT's ROE of -0.72%. Regarding short-term risk, KAPA is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs MRUS Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, MRUS has a market cap of 4B. Regarding current trading prices, KAPA is priced at $0.57, while MRUS trades at $53.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas MRUS's P/E ratio is -12.76. In terms of profitability, KAPA's ROE is -0.99%, compared to MRUS's ROE of -0.41%. Regarding short-term risk, KAPA is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs RYTM Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, RYTM has a market cap of 3.9B. Regarding current trading prices, KAPA is priced at $0.57, while RYTM trades at $61.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas RYTM's P/E ratio is -22.13. In terms of profitability, KAPA's ROE is -0.99%, compared to RYTM's ROE of -1.80%. Regarding short-term risk, KAPA is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs SLNO Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, SLNO has a market cap of 3.9B. Regarding current trading prices, KAPA is priced at $0.57, while SLNO trades at $77.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas SLNO's P/E ratio is -16.37. In terms of profitability, KAPA's ROE is -0.99%, compared to SLNO's ROE of -0.78%. Regarding short-term risk, KAPA is more volatile compared to SLNO. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs CYTK Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, CYTK has a market cap of 3.9B. Regarding current trading prices, KAPA is priced at $0.57, while CYTK trades at $32.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas CYTK's P/E ratio is -6.15. In terms of profitability, KAPA's ROE is -0.99%, compared to CYTK's ROE of +8.01%. Regarding short-term risk, KAPA is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs ACAD Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, ACAD has a market cap of 3.8B. Regarding current trading prices, KAPA is priced at $0.57, while ACAD trades at $22.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas ACAD's P/E ratio is 16.64. In terms of profitability, KAPA's ROE is -0.99%, compared to ACAD's ROE of +0.35%. Regarding short-term risk, KAPA is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs KRYS Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, KRYS has a market cap of 3.8B. Regarding current trading prices, KAPA is priced at $0.57, while KRYS trades at $130.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas KRYS's P/E ratio is 31.18. In terms of profitability, KAPA's ROE is -0.99%, compared to KRYS's ROE of +0.14%. Regarding short-term risk, KAPA is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs RYZB Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, KAPA is priced at $0.57, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas RYZB's P/E ratio is -57.86. In terms of profitability, KAPA's ROE is -0.99%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, KAPA is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs CRSP Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, CRSP has a market cap of 3.7B. Regarding current trading prices, KAPA is priced at $0.57, while CRSP trades at $43.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas CRSP's P/E ratio is -9.61. In terms of profitability, KAPA's ROE is -0.99%, compared to CRSP's ROE of -0.20%. Regarding short-term risk, KAPA is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs CBAY Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, KAPA is priced at $0.57, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas CBAY's P/E ratio is -32.81. In terms of profitability, KAPA's ROE is -0.99%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, KAPA is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs RNA Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, RNA has a market cap of 3.5B. Regarding current trading prices, KAPA is priced at $0.57, while RNA trades at $29.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas RNA's P/E ratio is -9.79. In terms of profitability, KAPA's ROE is -0.99%, compared to RNA's ROE of -0.27%. Regarding short-term risk, KAPA is more volatile compared to RNA. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs SWTX Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, KAPA is priced at $0.57, while SWTX trades at $46.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas SWTX's P/E ratio is -13.74. In terms of profitability, KAPA's ROE is -0.99%, compared to SWTX's ROE of -0.51%. Regarding short-term risk, KAPA is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs RARE Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, RARE has a market cap of 3.5B. Regarding current trading prices, KAPA is priced at $0.57, while RARE trades at $36.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas RARE's P/E ratio is -6.29. In terms of profitability, KAPA's ROE is -0.99%, compared to RARE's ROE of -1.86%. Regarding short-term risk, KAPA is more volatile compared to RARE. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs ACLX Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, ACLX has a market cap of 3.5B. Regarding current trading prices, KAPA is priced at $0.57, while ACLX trades at $62.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas ACLX's P/E ratio is -21.03. In terms of profitability, KAPA's ROE is -0.99%, compared to ACLX's ROE of -0.35%. Regarding short-term risk, KAPA is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs PTGX Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, PTGX has a market cap of 3.4B. Regarding current trading prices, KAPA is priced at $0.57, while PTGX trades at $55.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas PTGX's P/E ratio is 70.78. In terms of profitability, KAPA's ROE is -0.99%, compared to PTGX's ROE of +0.09%. Regarding short-term risk, KAPA is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs LEGN Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, LEGN has a market cap of 3.2B. Regarding current trading prices, KAPA is priced at $0.57, while LEGN trades at $34.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas LEGN's P/E ratio is -29.41. In terms of profitability, KAPA's ROE is -0.99%, compared to LEGN's ROE of -0.20%. Regarding short-term risk, KAPA is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs KYMR Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, KYMR has a market cap of 3B. Regarding current trading prices, KAPA is priced at $0.57, while KYMR trades at $46.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas KYMR's P/E ratio is -14.90. In terms of profitability, KAPA's ROE is -0.99%, compared to KYMR's ROE of -0.30%. Regarding short-term risk, KAPA is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs VKTX Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, VKTX has a market cap of 3B. Regarding current trading prices, KAPA is priced at $0.57, while VKTX trades at $26.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas VKTX's P/E ratio is -22.78. In terms of profitability, KAPA's ROE is -0.99%, compared to VKTX's ROE of -0.14%. Regarding short-term risk, KAPA is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs SRRK Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, SRRK has a market cap of 3B. Regarding current trading prices, KAPA is priced at $0.57, while SRRK trades at $31.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas SRRK's P/E ratio is -12.22. In terms of profitability, KAPA's ROE is -0.99%, compared to SRRK's ROE of -1.18%. Regarding short-term risk, KAPA is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs CRNX Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, CRNX has a market cap of 2.9B. Regarding current trading prices, KAPA is priced at $0.57, while CRNX trades at $30.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas CRNX's P/E ratio is -8.12. In terms of profitability, KAPA's ROE is -0.99%, compared to CRNX's ROE of -0.31%. Regarding short-term risk, KAPA is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs MORF Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, KAPA is priced at $0.57, while MORF trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas MORF's P/E ratio is -14.88. In terms of profitability, KAPA's ROE is -0.99%, compared to MORF's ROE of -0.22%. Regarding short-term risk, KAPA is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs MOR Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, KAPA is priced at $0.57, while MOR trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas MOR's P/E ratio is -12.64. In terms of profitability, KAPA's ROE is -0.99%, compared to MOR's ROE of +2.51%. Regarding short-term risk, KAPA is more volatile compared to MOR. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs CPRX Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, CPRX has a market cap of 2.8B. Regarding current trading prices, KAPA is priced at $0.57, while CPRX trades at $23.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas CPRX's P/E ratio is 14.79. In terms of profitability, KAPA's ROE is -0.99%, compared to CPRX's ROE of +0.28%. Regarding short-term risk, KAPA is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs AAPG Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, AAPG has a market cap of 2.7B. Regarding current trading prices, KAPA is priced at $0.57, while AAPG trades at $31.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas AAPG's P/E ratio is -42.76. In terms of profitability, KAPA's ROE is -0.99%, compared to AAPG's ROE of -2.50%. Regarding short-term risk, KAPA is more volatile compared to AAPG. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs MLTX Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, MLTX has a market cap of 2.7B. Regarding current trading prices, KAPA is priced at $0.57, while MLTX trades at $43.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas MLTX's P/E ratio is -18.70. In terms of profitability, KAPA's ROE is -0.99%, compared to MLTX's ROE of -0.00%. Regarding short-term risk, KAPA is more volatile compared to MLTX. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs KDNY Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, KDNY has a market cap of 2.7B. Regarding current trading prices, KAPA is priced at $0.57, while KDNY trades at $40.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas KDNY's P/E ratio is -12.47. In terms of profitability, KAPA's ROE is -0.99%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, KAPA is more volatile compared to KDNY. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs MTSR Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, MTSR has a market cap of 2.7B. Regarding current trading prices, KAPA is priced at $0.57, while MTSR trades at $25.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas MTSR's P/E ratio is -10.03. In terms of profitability, KAPA's ROE is -0.99%, compared to MTSR's ROE of -0.63%. Regarding short-term risk, KAPA is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs MYOV Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, MYOV has a market cap of 2.6B. Regarding current trading prices, KAPA is priced at $0.57, while MYOV trades at $26.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas MYOV's P/E ratio is -14.05. In terms of profitability, KAPA's ROE is -0.99%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, KAPA is more volatile compared to MYOV. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs IMVT Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, IMVT has a market cap of 2.6B. Regarding current trading prices, KAPA is priced at $0.57, while IMVT trades at $15.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas IMVT's P/E ratio is -5.61. In terms of profitability, KAPA's ROE is -0.99%, compared to IMVT's ROE of -0.81%. Regarding short-term risk, KAPA is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs MIRM Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, MIRM has a market cap of 2.5B. Regarding current trading prices, KAPA is priced at $0.57, while MIRM trades at $50.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas MIRM's P/E ratio is -31.49. In terms of profitability, KAPA's ROE is -0.99%, compared to MIRM's ROE of -0.34%. Regarding short-term risk, KAPA is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs IBRX Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, IBRX has a market cap of 2.5B. Regarding current trading prices, KAPA is priced at $0.57, while IBRX trades at $2.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas IBRX's P/E ratio is -4.98. In terms of profitability, KAPA's ROE is -0.99%, compared to IBRX's ROE of +0.65%. Regarding short-term risk, KAPA is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs APGE Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, APGE has a market cap of 2.5B. Regarding current trading prices, KAPA is priced at $0.57, while APGE trades at $41.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas APGE's P/E ratio is -11.54. In terms of profitability, KAPA's ROE is -0.99%, compared to APGE's ROE of -0.19%. Regarding short-term risk, KAPA is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs XENE Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, XENE has a market cap of 2.4B. Regarding current trading prices, KAPA is priced at $0.57, while XENE trades at $31.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas XENE's P/E ratio is -9.84. In terms of profitability, KAPA's ROE is -0.99%, compared to XENE's ROE of -0.32%. Regarding short-term risk, KAPA is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs NAMSW Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, NAMSW has a market cap of 2.4B. Regarding current trading prices, KAPA is priced at $0.57, while NAMSW trades at $9.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas NAMSW's P/E ratio is N/A. In terms of profitability, KAPA's ROE is -0.99%, compared to NAMSW's ROE of -0.33%. Regarding short-term risk, KAPA is more volatile compared to NAMSW. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs PRVB Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, PRVB has a market cap of 2.4B. Regarding current trading prices, KAPA is priced at $0.57, while PRVB trades at $24.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas PRVB's P/E ratio is -16.43. In terms of profitability, KAPA's ROE is -0.99%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, KAPA is more volatile compared to PRVB. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs LBPH Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, LBPH has a market cap of 2.3B. Regarding current trading prices, KAPA is priced at $0.57, while LBPH trades at $59.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas LBPH's P/E ratio is -26.66. In terms of profitability, KAPA's ROE is -0.99%, compared to LBPH's ROE of -0.33%. Regarding short-term risk, KAPA is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs DICE Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, DICE has a market cap of 2.3B. Regarding current trading prices, KAPA is priced at $0.57, while DICE trades at $47.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas DICE's P/E ratio is -21.91. In terms of profitability, KAPA's ROE is -0.99%, compared to DICE's ROE of +0.56%. Regarding short-term risk, KAPA is more volatile compared to DICE. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs APLS Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, APLS has a market cap of 2.2B. Regarding current trading prices, KAPA is priced at $0.57, while APLS trades at $17.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas APLS's P/E ratio is -9.86. In terms of profitability, KAPA's ROE is -0.99%, compared to APLS's ROE of -1.00%. Regarding short-term risk, KAPA is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs LGND Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, LGND has a market cap of 2.2B. Regarding current trading prices, KAPA is priced at $0.57, while LGND trades at $112.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas LGND's P/E ratio is -15.44. In terms of profitability, KAPA's ROE is -0.99%, compared to LGND's ROE of -0.16%. Regarding short-term risk, KAPA is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs CALT Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, CALT has a market cap of 2.1B. Regarding current trading prices, KAPA is priced at $0.57, while CALT trades at $40.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas CALT's P/E ratio is -22.73. In terms of profitability, KAPA's ROE is -0.99%, compared to CALT's ROE of -1.67%. Regarding short-term risk, KAPA is more volatile compared to CALT. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs ARWR Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, ARWR has a market cap of 2.1B. Regarding current trading prices, KAPA is priced at $0.57, while ARWR trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas ARWR's P/E ratio is -12.50. In terms of profitability, KAPA's ROE is -0.99%, compared to ARWR's ROE of -0.47%. Regarding short-term risk, KAPA is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs SRPT Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, SRPT has a market cap of 2.1B. Regarding current trading prices, KAPA is priced at $0.57, while SRPT trades at $21.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas SRPT's P/E ratio is -8.14. In terms of profitability, KAPA's ROE is -0.99%, compared to SRPT's ROE of -0.20%. Regarding short-term risk, KAPA is more volatile compared to SRPT. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs VCYT Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, VCYT has a market cap of 2.1B. Regarding current trading prices, KAPA is priced at $0.57, while VCYT trades at $26.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas VCYT's P/E ratio is 63.71. In terms of profitability, KAPA's ROE is -0.99%, compared to VCYT's ROE of +0.03%. Regarding short-term risk, KAPA is more volatile compared to VCYT. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs VCEL Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, VCEL has a market cap of 2.1B. Regarding current trading prices, KAPA is priced at $0.57, while VCEL trades at $41.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas VCEL's P/E ratio is 830.00. In terms of profitability, KAPA's ROE is -0.99%, compared to VCEL's ROE of +0.01%. Regarding short-term risk, KAPA is more volatile compared to VCEL. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs BCRX Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, BCRX has a market cap of 2.1B. Regarding current trading prices, KAPA is priced at $0.57, while BCRX trades at $9.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas BCRX's P/E ratio is -38.35. In terms of profitability, KAPA's ROE is -0.99%, compared to BCRX's ROE of +0.11%. Regarding short-term risk, KAPA is more volatile compared to BCRX. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs NAMS Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, NAMS has a market cap of 2.1B. Regarding current trading prices, KAPA is priced at $0.57, while NAMS trades at $18.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas NAMS's P/E ratio is -10.07. In terms of profitability, KAPA's ROE is -0.99%, compared to NAMS's ROE of -0.33%. Regarding short-term risk, KAPA is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs KNSA Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, KNSA has a market cap of 2B. Regarding current trading prices, KAPA is priced at $0.57, while KNSA trades at $27.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas KNSA's P/E ratio is -116.46. In terms of profitability, KAPA's ROE is -0.99%, compared to KNSA's ROE of -0.04%. Regarding short-term risk, KAPA is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs DNLI Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, DNLI has a market cap of 2B. Regarding current trading prices, KAPA is priced at $0.57, while DNLI trades at $14.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas DNLI's P/E ratio is -5.35. In terms of profitability, KAPA's ROE is -0.99%, compared to DNLI's ROE of -0.36%. Regarding short-term risk, KAPA is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs AGIO Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, AGIO has a market cap of 2B. Regarding current trading prices, KAPA is priced at $0.57, while AGIO trades at $34.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas AGIO's P/E ratio is 3.01. In terms of profitability, KAPA's ROE is -0.99%, compared to AGIO's ROE of +0.50%. Regarding short-term risk, KAPA is more volatile compared to AGIO. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.
KAPA vs CGON Comparison
KAPA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KAPA stands at 9.6M. In comparison, CGON has a market cap of 2B. Regarding current trading prices, KAPA is priced at $0.57, while CGON trades at $26.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KAPA currently has a P/E ratio of -2.60, whereas CGON's P/E ratio is -17.49. In terms of profitability, KAPA's ROE is -0.99%, compared to CGON's ROE of -0.17%. Regarding short-term risk, KAPA is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for KAPA.